On Oct. 3, Research and Information Specialist Ilsa Jerome, Ph.D., Clinical Research Associate Berra Yazar-Klosinski, Ph.D., and Executive Director Rick Doblin, Ph.D., finalized the study design for our investigation of marijuana as a treatment for Posttraumatic Stress Disorder (PTSD). We are preparing to submit the protocol and informed consent forms to the FDA by the end of this month. We currently consider marijuana usage to be more useful in treating symptoms of PTSD and requiring regular administration, while MDMA-assisted psychotherapy is aimed at achieving a cure by getting to the core of the problem.